Summary of Key Points from the Conference Call Company and Industry Overview - The conference call focuses on **Juzhibio** and its brand **Kefumei**, which operates in the **recombinant collagen protein** market, currently valued at approximately **400 billion RMB** [4][2]. Core Insights and Arguments - **Sales Impact from Public Relations Incident**: A recent incident involving a video by a chemist questioning the collagen content in Kefumei's products led to a significant drop in sales. The target growth rate for the 618 sales period was **60%**, but actual growth was only **20%-30%**. Sales on Douyin dropped by **50%** following the incident [2][22]. - **Long-term Market Potential**: Despite short-term setbacks, the long-term outlook for the recombinant collagen market remains positive, driven by market segmentation and the introduction of new collagen products (types IV and XVII) [1][4]. - **Product Performance**: The **Kefumei collagen stick** is a core product, with a pre-pandemic growth expectation of **50%**. It has a high repurchase rate of **70%-80%**, with new customer acquisition at nearly **50%** [1][6]. The **Focus Cream**, launched eight months ago, generated **200 million RMB** in revenue but has a low repurchase rate of **20%** due to its long improvement cycle [7][8]. - **Brand Loyalty and Customer Retention**: The brand enjoys a high level of recognition and loyalty among existing customers, with a repurchase rate of **40%** during key sales events, indicating strong customer satisfaction [12][11]. Additional Important Insights - **Channel Strategy**: Juzhibio is enhancing its online and offline channel operations, with plans to open **20 new direct stores** to improve customer engagement and service capabilities [16][14]. - **Market Competition**: The recombinant collagen market is becoming increasingly competitive, with several brands entering the space. However, the lack of regulatory barriers in the cosmetics sector allows for market expansion rather than intensified competition [24][25]. - **Impact of Pricing and Promotions**: The pricing strategy for the collagen stick has seen a **25%** increase in consumer feedback during the 618 period, indicating a shift in consumer perception and potential challenges in maintaining sales momentum [6][25]. - **Future Growth Opportunities**: The company is exploring new growth points through product bundling and marketing strategies, particularly for the Focus Cream, which is positioned as a secondary growth driver [23][19]. Conclusion - Juzhibio's long-term growth potential in the recombinant collagen market remains strong despite recent challenges. The company is actively working to enhance its product offerings, customer engagement strategies, and market positioning to navigate the competitive landscape and capitalize on future opportunities.

Group 1 - The beauty and personal care sector has shown strong performance in Q1 2025, with the SW Beauty Care Index rising by 13.4%, leading all 31 SW primary industries [4][10][12] - The cosmetics segment is focusing on enhancing brand matrices and introducing new ingredients, benefiting from an optimized competitive landscape [4][6] - The medical beauty market is evolving with new products stimulating consumer interest, and domestic companies are expected to become major competitors in the light medical beauty sector [4][6] Group 2 - The e-commerce sector is witnessing new consumption models and brands, which are helping to drive growth in the industry [4][6] - The report recommends several companies in the cosmetics sector, including Up Beauty and Proya, which have low PE multiples and strong growth potential [4][6] - In the medical beauty segment, companies with high R&D barriers and strong profitability, such as Aimeike, are highlighted as key investment opportunities [4][6] Group 3 - The personal care market is projected to reach CNY 283.3 billion by 2024, with a compound annual growth rate (CAGR) of 8.4% from 2023 to 2028 [32][34] - Domestic brands are increasingly replacing foreign brands in the personal care sector, with a notable rise in innovative products and marketing strategies [32][36] - The high-end market is experiencing significant growth, with premium products seeing a 27% increase in average transaction value in H2 2024 [44]

Core Viewpoint - The article emphasizes the importance of the "self-care" concept in the skincare industry, highlighting how brands like Keli Jin are redefining anti-aging narratives by integrating cultural philosophies and emotional connections into their products and experiences [4][10][22]. Group 1: Brand Activities and Philosophy - Keli Jin's event "My 'Reorganization' Energy" in Chengdu reflects a shift towards creating a gentle space for urban dwellers, focusing on self-awareness and emotional needs through skincare [2][4]. - The brand utilizes Eastern wellness philosophies, such as "regulating energy, following trends, and maintaining harmony," to connect skincare with personal well-being [2][7]. - The event featured activities like morning exercises and DIY scent bags, which engage multiple senses and promote a holistic approach to skincare [6][8]. Group 2: Emotional Connection and Consumer Engagement - The concept of "self-care" has evolved into a crucial channel for brands to establish deeper relationships with younger consumers, who seek products that resonate with their lifestyles and emotional needs [4][10]. - Keli Jin aims to transition from a focus on product functionality to building emotional connections, making "self-care" a core element of its brand identity [4][10][12]. Group 3: Technological Integration and Product Development - Keli Jin leverages over 20 years of research in recombinant collagen technology, holding 167 patents and applications, positioning itself as a leader in this field [12][22]. - The brand's core ingredient, C5HA recombinant collagen, is scientifically formulated to enhance skin absorption and promote collagen production, addressing both efficacy and consumer trust [12][14]. - Keli Jin's product matrix includes a range of items designed for both morning and night use, catering to the growing demand for "time-specific care" and "certain efficacy" among consumers [16][18]. Group 4: Market Trends and Brand Strategy - The skincare industry is witnessing a structural shift where emotional resonance and understanding consumer needs are becoming as important as product efficacy [19][22]. - Keli Jin's dual strategy of combining "soft narrative" with "hard technology" allows it to build a brand model that is both scientifically grounded and emotionally engaging [22][30]. - The brand's approach to anti-aging is reframed from a battle against time to a gentle reorganization of one's state, aligning with modern consumer desires for self-acceptance and emotional well-being [29][30].

Core Viewpoint - The ongoing debate regarding "recombinant collagen" has raised significant industry and market attention, with the company emphasizing the need to correct misleading perceptions in the capital market that deviate from scientific and industrial fundamentals [1][2]. Group 1: Company Position on Recombinant Collagen - The company argues that recombinant collagen is a minor branch of collagen research and industrial transformation, with the main advancements in protein research being led by life science institutions and pharmaceutical companies, not cosmetic firms [1][2]. - The company highlights that there is currently no international approval for medical devices based on recombinant collagen, indicating the need for longer observation periods in this field [2]. - The company asserts that the growth of its hyaluronic acid business remains stable, with an annual growth rate exceeding 10%, while the recombinant collagen market lacks a mature international market comparable to hyaluronic acid [3][4]. Group 2: Market Dynamics and Performance - The company clarifies that its performance adjustments are not solely due to the rise of recombinant collagen, as its hyaluronic acid business continues to grow, particularly in the pharmaceutical-grade and overseas export segments, which have seen over 20% growth [3][4]. - The decline in overall performance is attributed to a downturn in consumer goods and one-time asset impairment losses, rather than the emergence of recombinant collagen as a competitive force [4]. - The company emphasizes that the concept of "recombinant collagen" is often misrepresented, as it does not meet the academic standards required for biological functionality [5][6]. Group 3: Industry Ecosystem and Communication - The company stresses the importance of establishing a credible foundation for domestic brands, which should not rely on the misuse of academic terms and concepts that mislead consumers [7]. - The company calls for a collaborative effort among industry participants, regulatory bodies, and media to enhance understanding and improve the overall ecosystem, ensuring that scientific and industrial developments are accurately represented [9]. - The company plans to strengthen professional communication with the capital market, recognizing the need for better understanding of the biological sciences among analysts and investors [8].

Core Viewpoint - The ongoing public dispute between two major players in the beauty industry, Huaxi Biological and Juzhi Biological, has escalated into a fierce battle over allegations of fraud and market manipulation, significantly impacting their market positions and stock prices [1][4][34]. Group 1: Background and Timeline - The conflict began on May 17 when Huaxi Biological publicly criticized several brokerage reports that favored Juzhi Biological's products, suggesting they misled the market [5][6]. - On May 24, beauty influencer Hao Yu accused Juzhi Biological of fraud regarding its "collagen stick" product, claiming the actual collagen content was only 0.0177%, far below the labeled 0.1% [16][17]. - Following these allegations, Juzhi Biological issued a rebuttal, presenting an internal quality inspection report to counter the fraud claims [18][19]. Group 2: Market Impact - Since the dispute began, Huaxi Biological's stock price has increased by approximately 6.8%, while Juzhi Biological's stock has seen a cumulative decline of 25.20%, resulting in a market value loss of over 16 billion HKD [34]. - The consumer market has also reacted, with Juzhi Biological's product ranking dropping significantly on e-commerce platforms, indicating a shift in consumer perception [36]. Group 3: Industry Dynamics - The conflict highlights a broader competition between two factions in the beauty industry: the hyaluronic acid camp represented by Huaxi Biological and the recombinant collagen camp led by Juzhi Biological [39]. - The rise of recombinant collagen products has been attributed to a lack of standardized regulations and testing methods, allowing companies like Juzhi Biological to capitalize on marketing without stringent scientific backing [41]. - In contrast, Huaxi Biological has faced significant challenges, with its market value plummeting from 140 billion to 26.1 billion, while Juzhi Biological's market capitalization has surged by 230% since its IPO [37].

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry, indicating potential growth opportunities in the sector [2]. Core Insights - The domestic brands showcased strong performance on Douyin, with Feicui achieving a GMV of nearly 500 million, marking a new high for the year [6][12]. - The cosmetics and medical beauty sector performed in line with the market, with the Shenwan Beauty Care Index rising by 1.6% from May 30 to June 6, 2025 [6][7]. - International cosmetic companies are experiencing a decline or slowdown in growth, with L'Oréal's Q1 2025 revenue growth at 4.4%, and Estée Lauder facing a significant drop in revenue and operating profit [13][15][16]. Summary by Sections Industry Performance - The Shenwan Beauty Care Index increased by 1.6%, while the Shenwan Cosmetics Index rose by 0.7%, slightly underperforming the Shenwan A Index [6][7]. - Domestic brands like Marubi and Yilian have shown over 50% growth in skincare, while color cosmetics brands like Caitang and Maogeping achieved over 70% growth [12]. Key Developments - Leping Medical's "童颜针" (Youthful Needle) received approval, marking a competitive entry into the domestic market for facial fillers [26]. - Furuida's synthetic royal jelly acid (10-HDA) has achieved industrialization, providing a high-purity ingredient for anti-aging products [27]. Investment Recommendations - Recommended stocks include: 1. Upstream companies with strong R&D capabilities and profitability, such as Aimeike [17]. 2. Brands benefiting from Douyin traffic, like Marubi [17]. 3. Companies with strong product innovation and cost-effectiveness, such as Runben and Furuida [17]. - Suggested to pay attention to Shanghai Jahwa, Betaini, Huaxi Biological, and Water Sheep [17]. Market Trends - The cosmetics market in China is projected to grow, with a retail sales increase of 7.2% in April 2025, indicating a recovery in consumer demand [23][25]. - The market share of domestic brands in the skincare segment has improved significantly, with domestic brands occupying five out of the top ten positions in market share [36][37].

Core Viewpoint - The controversy surrounding the product "Kefumei" from Juzhi Biotechnology has escalated into a significant public debate over the authenticity of its key ingredient, recombinant collagen, leading to a broader discussion about ingredient marketing in the domestic beauty industry [1][3][4]. Group 1: Incident Overview - The dispute began on May 24 when beauty blogger "Dr. Big Mouth" Hao Yu accused Juzhi Biotechnology of falsely advertising the collagen content in its "Kefumei" product, claiming the actual amount was only 0.0177%, while it should be above 0.1% to comply with regulations [3][4]. - Juzhi Biotechnology responded with its own testing results, asserting compliance, but the blogger continued to question the validity of these results, leading to a back-and-forth that has lasted 12 days [3][4]. - The incident has resulted in a significant market impact, with Juzhi Biotechnology's market value dropping by over 20%, amounting to nearly 20 billion HKD [4]. Group 2: Industry Context - The beauty industry in China has increasingly relied on ingredient marketing, with companies like Huaxi Biotechnology leveraging popular ingredients like hyaluronic acid to drive sales [5][6]. - Juzhi Biotechnology's revenue for 2024 is projected to reach 5.54 billion RMB, a 57.2% increase year-on-year, with the "Kefumei" brand contributing over 80% of this revenue [4][6]. - The reliance on e-commerce channels is evident, with direct-to-consumer (DTC) sales accounting for 71.6% of Juzhi's total revenue, up from 65.2% the previous year [6]. Group 3: Market Dynamics - The ongoing debate highlights a "arms race" in ingredient marketing within the domestic beauty sector, where companies must continuously innovate and promote new ingredients to attract consumer interest and investment [1][5]. - The lack of industry standards for new ingredients like recombinant collagen complicates the situation, as companies can interpret and market these ingredients in ways that may not align with consumer expectations [10][11]. - The competitive landscape is further complicated by the contrasting fortunes of companies like Juzhi Biotechnology, which has seen its valuation rise, versus Huaxi Biotechnology, which has experienced declining revenues and profits [8][9].

Group 1 - Jialong Co. expects its soy sauce products to be launched in the second half of the year, with progress on the business proceeding smoothly [1] - Babi Foods reports that the median order amount for stores in East China has turned positive year-on-year for April and May, with a stable closure rate [2] - Muyuan Foods announces a sales revenue of 12.258 billion yuan from commodity pigs in May, reflecting a year-on-year increase of 26.93% [3] Group 2 - Haitian Flavor Industry's board has approved the global offering of H-shares and listing on the Hong Kong Stock Exchange [4] - Wens Foodstuff Group has undergone a change in actual controllers, with a new agreement signed by ten individuals, holding a combined 11.94% of the total share capital [5] - White Elephant Foods clarifies that its "Duoban" products are larger versions of existing products and will adjust packaging to avoid consumer confusion [6] Group 3 - Juzhi Biotechnology confirms that its recombinant collagen products contain real added collagen, with testing results showing content greater than 0.1% [7][8] - *ST Renle announces that its stock will enter a delisting arrangement period starting June 13, 2025, with the last trading day expected to be July 3, 2025 [9] - The involved blogger in the "Red Underwear" case related to Pang Donglai has issued an apology video, complying with the court's judgment [10]

Core Viewpoint - The ongoing controversy surrounding the collagen content claims by Juzhi Biotechnology highlights a deeper crisis of trust within the skincare industry, exacerbated by a lack of transparency and regulatory standards [1][2][3]. Group 1: Industry Trust Issues - The dispute over ingredient authenticity has revealed significant gaps in consumer trust and industry standards, with companies often engaging in "black box" practices that obscure the true efficacy of their products [3][4]. - The skincare sector is facing a crisis where consumers are increasingly skeptical of scientific claims, demanding transparency and accountability from brands [3][10]. Group 2: Regulatory and Market Dynamics - Recent events, including a fine imposed on CSS for false advertising, illustrate the consequences of misleading marketing practices, with penalties disproportionately affecting downstream partners rather than brands [6][9]. - The market for soluble collagen and other active ingredients is experiencing explosive growth, with a reported 106.93% increase in soluble collagen registrations, indicating a shift in consumer preferences towards these components [6][9]. Group 3: Ingredient Efficacy and Marketing Practices - The industry is grappling with two main issues: the imbalance in quantifying ingredient efficacy and the use of "shadow ingredients" to mislead consumers about product value [7][8]. - Companies are often reducing the actual amounts of active ingredients to cut costs, leading to a significant disparity between product claims and actual performance, which undermines consumer trust [7][8]. Group 4: Future Opportunities and Challenges - The lack of standardized testing methods and regulatory frameworks is creating a fragmented market where companies can exploit loopholes, leading to a potential collapse of consumer confidence [10][11]. - The need for an open and transparent verification platform is critical for establishing trust and setting future industry standards, as current practices are failing to meet consumer expectations [10][11].

Core Viewpoint - The controversy surrounding the collagen products of Juzhi Biotechnology has intensified, with beauty blogger "Dr. Big Mouth" questioning the validity of the company's testing reports and the lack of transparency regarding the testing institutions involved [1][2]. Group 1: Company Response - Juzhi Biotechnology claims that multiple authoritative testing institutions have confirmed the presence of recombinant collagen in their products, specifically in the "Human-like Recombinant Collagen Essence" [1]. - The company asserts that the collagen content is greater than 0.1% and that the product has been sold out across various channels, countering claims of a "quiet removal" from the market [1]. Group 2: Critic's Concerns - The critic highlights four main doubts regarding the testing reports: 1. The use of different testing methods raises questions about the accuracy and consistency of results, particularly why a less precise method was used instead of a high-precision mass spectrometry method [2]. 2. The claim of 100% homology with human collagen is disputed, as the critic points out that the company's own patent indicates only 86% homology when using standard comparison methods [2]. 3. The absence of blank controls in the double biuret method testing is questioned, as it is unclear how the base components of the formula affect the results [2]. 4. The lack of names and seals from the testing institutions on the reports is criticized, suggesting that the reports lack credibility and transparency [2].